Niterra Ventures Company Invests $18M Additional Funding in Neoplas Med GmbH
Summary
"The additional investment by Niterra Ventures Company opens up completely new opportunities for us to tap into further markets, expand our technology platform and develop new products," said Ulrike Sailer, CEO of Neoplas Med. "As a part of its effort in medical, Niterra Ventures Company is investing in technology detecting and assessing cardiology, oncology, neurology and hypertension conditions.Around two million people in Germany suffer from serious miracle diseases. Neoplas Med GmbH is advancing the fascinating possibilities of argon cold plasma jet therapy in clinical use and is thus working to effectively and sustainably improve the quality of life of people with acute and chronic wounds. To ensure that the new cold plasma jet therapy can be reimbursed by the German public health insurances, Neoplas Med submitted an application for the trial study back in April 2021, which was approved by the Federal Joint Committee (G-BA) in February 2023. The National Association of Statutory Health Insurance Physicians recently published the decision of the Supplementary Evaluation Committee on the reimbursement of service providers for the trial study Cold plasma for chronic wounds.